Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Jun Xia 1 Article
Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma
Jin-Hua Liang, Yun-Ping Zhang, Jun Xia, Chong-Yang Ding, Wei Wu, Li Wang, Lei Cao, Hua-Yuan Zhu, Lei Fan, Tian-Nv Li, Jian-Yong Li, Wei Xu
Cancer Res Treat. 2019;51(4):1479-1487.   Published online March 12, 2019
DOI: https://doi.org/10.4143/crt.2018.649
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the prognostic significance of total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) in patients with follicular lymphoma (FL) at baseline and mid-treatment with 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) scans.
Methods
The study analyzed data from 48 patients with FL who were treated in Jiangsu Province Hospital and reviewed their baseline PET-CT scans. TMTV and TLG were computed by using the absolute value of 2.0, 2.5, and 3.0 thresholding method, respectively.
Results
Median age was 53 years, 75.0% of patients had stage III to IV disease, 43.8% had a Follicular Lymphoma International Prognostic Index 1 (FLIPI1) score of 3 to 5 and 20.8% had a FLIPI2 score of 3 to 5. Receiver operating characteristic (ROC) curve analysis showed the optimal cut-off values for TMTV3.0 and TLG3.0 were 476.4 (sensitivity, 85.7%; specificity, 78.0%; area under the curve [AUC], 0.760; p=0.003) and 2,676.9 (sensitivity, 71.4%; specificity, 78.0%; AUC, 0.760; p=0.003). On multivariable analysis, TMTV3.0 and TLG3.0 were independent predictors of both progression-free survival (PFS) (hazard ratio [HR], 5.406; 95% confidence interval [CI], 1.326 to 22.040; p=0.019 and HR, 6.502; 95% CI, 1.079 to 39.182; p=0.042) and overall survival (OS) (HR, 4.111; 95% CI, 1.125 to 15.027; p=0.033 and HR, 5.885; 95% CI, 1.014 to 34.148; p=0.049). ROC curve analysis showed the optimal cut-off values for ΔTMTV3.0 and ΔTLG3.0 were 66.3% (sensitivity, 85.7%; specificity, 63.4%; AUC, 0.774; p < 0.001) and 64.5% (sensitivity, 85.7%; specificity, 65.9%; AUC, 0.777; p < 0.001).
Conclusion
Baseline TMTV and TLG are strong predictors of PFS and OS in FL. Furthermore, interim TMTV (ΔTMTV > 66.3%) and TLG (ΔTLG > 64.5%) reduction are valuable tools for early treatment response assessment in FL patients.

Citations

Citations to this article as recorded by  
  • Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy
    Nan Wang, Xin‐Yun Huang, Xu‐Feng Jiang, Li Wang, Shu Cheng, Peng‐Peng Xu, Lei Dong, Bin‐Shen Ou‐Yang, Rong‐Ji Mu, Chen Li, Yan Zhao, Yan Feng, Hong‐Jing Dou, Zhong Zheng, Wei‐Li Zhao
    Hematological Oncology.2025;[Epub]     CrossRef
  • The Predictive Role of Baseline 18F-FDG PET/CT Radiomics in Follicular Lymphoma on Watchful Waiting: A Preliminary Study
    Daria Maccora, Michele Guerreri, Rosalia Malafronte, Francesco D’Alò, Stefan Hohaus, Marco De Summa, Vittoria Rufini, Roberto Gatta, Luca Boldrini, Lucia Leccisotti, Salvatore Annunziata
    Diagnostics.2025; 15(4): 432.     CrossRef
  • Baseline [18F]FDG PET/CT radiomics for predicting interim efficacy in follicular lymphoma treated with first-line R-CHOP
    Zeying Wen, Xiaohe Gao, Qingxia Wu, Jianwei Yang, Jian Sun, Keliu Wu, Hongfei Zhao, Ruihua Wang, Yanmei Li
    BMC Cancer.2025;[Epub]     CrossRef
  • A novel prognostic model utilizing TMTV and SUVmax from 18F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma
    Hua Wang, Demei Feng, Yiwen Mo, Huangming Hong, Yingying Hu, Li Huang, Xiaolei Wei, Yajun Li, Haibin Huang, Runhui Zheng, Yonghua Li, Hui Zeng, Robert Peter Gale, Tian Ying, Jing Guo, Zhenshu Xu, Wei Fan, Tongyu Lin
    BMC Cancer.2025;[Epub]     CrossRef
  • Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma
    Shijia Cheng, Yanyan Liu
    Current Treatment Options in Oncology.2025; 26(4): 313.     CrossRef
  • Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the FOLL12 Trial
    Rexhep Durmo, Stephane Chauvie, Carla Minoia, Fabrizio Bergesio, Federico Fallanca, Simona Peano, Luigi Marcheselli, Antonella Anastasia, Carola Boccomini, Paolo Corradini, Jacopo Olivieri, Luca Arcaini, Federica Cavallo, Adalberto Ibatici, Luca Nassi, Vi
    American Journal of Hematology.2025;[Epub]     CrossRef
  • Personalised therapy in follicular lymphoma – is the dial turning?
    Kim M. Linton, Lena Specht, Astrid Pavlovsky, Carrie A. Thompson, Eva Kimby, Daphne de Jong, Loretta J. Nastoupil, Anne‐Ségolène Cottereau, Carla Casulo, Clémentine Sarkozy, Jessica Okosun
    Hematological Oncology.2024;[Epub]     CrossRef
  • Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
    A.S. Cottereau, L. Rebaud, J. Trotman, P. Feugier, L.J. Nastoupil, E. Bachy, I.W. Flinn, C. Haioun, L. Ysebaert, N.L. Bartlett, H. Tilly, O. Casasnovas, R. Ricci, C. Portugues, I. Buvat, M. Meignan, F. Morschhauser
    Annals of Oncology.2024; 35(1): 130.     CrossRef
  • Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma
    S. Draye-Carbonnier, V. Camus, S. Becker, D. Tonnelet, E. Lévêque, A. Zduniak, F. Jardin, H. Tilly, P. Vera, P. Decazes
    Scientific Reports.2024;[Epub]     CrossRef
  • Baseline 18F-FDG PET/CT may contribute to the determination of initial treatment strategy for newly diagnosed follicular lymphoma
    Qiao Yang, Hongzhe Zhang, Yan Zhang, Wei Zhang, Daobin Zhou, Yaping Luo
    European Journal of Radiology.2024; 178: 111632.     CrossRef
  • The value of semiquantitative PET features and end‐of‐therapy PET in grade 3B follicular lymphoma
    Allison Barraclough, Sze Ting Lee, Diego Villa, Greg Hapgood, Don Wilson, Geoffrey Chong, Eliza A. Hawkes
    British Journal of Haematology.2024; 205(6): 2254.     CrossRef
  • Semiquantitative 2-[18F]FDG PET/CT-based parameters role in lymphoma
    Domenico Albano, Marco Ravanelli, Rexhep Durmo, Annibale Versari, Angelina Filice, Alessio Rizzo, Manuela Racca, Daniele Antonio Pizzuto, Francesco Bertagna, Salvatore Annunziata
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation‐Wide cohort study
    Isabel Ródenas‐Quiñonero, Tzu Chen‐Liang, Taida Martín‐Santos, Antonio Salar, Marta Fernández‐González, Carolina Celades, José‐Tomás Navarro, Ana Belén Martínez‐Garcia, Rafael Andreu, Aitana Balaguer, Alejandro Martin García‐Sancho, Mónica Baile, Javier L
    Cancer Medicine.2023; 12(6): 6536.     CrossRef
  • Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL)
    Yiting Xie, Yue Teng, Chong Jiang, Chongyang Ding, Zhengyang Zhou
    Japanese Journal of Radiology.2023; 41(7): 777.     CrossRef
  • Prognostic value of interim 18F-FDG PET/CT in adult follicular lymphoma treated with R-CHOP
    Na Sun, Wenli Qiao, Yan Xing, Taisong Wang, Jinhua Zhao
    Annals of Hematology.2023; 102(4): 795.     CrossRef
  • Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
    Wojciech Cytawa, Robin Hendel, Bartłomiej Tomasik, Franz-Xaver Weinzierl, Thorsten Bley, Jacek Jassem, Andreas Schirbel, Andreas K. Buck, Ralph A. Bundschuh, Philipp E. Hartrampf, Rudolf A. Werner, Constantin Lapa
    European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(12): 3765.     CrossRef
  • Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy
    Florian Rosar, Felix Wenner, Fadi Khreish, Sebastian Dewes, Gudrun Wagenpfeil, Manuela A. Hoffmann, Mathias Schreckenberger, Mark Bartholomä, Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging.2022; 49(5): 1584.     CrossRef
  • Prognostic significance of clinical characteristics and 18Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma
    Yizhen Liu, Jinjin Jiang, Lianfang Liu, Zezhou Wang, Baohua Yu, Zuguang Xia, Qunling Zhang, Dongmei Ji, Xiaojian Liu, Fangfang Lv, Xiaonan Hong, Shaoli Song, Junning Cao
    Journal of International Medical Research.2022;[Epub]     CrossRef
  • Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
    Tarec Christoffer El‐Galaly, Diego Villa, Chan Yoon Cheah, Lars C. Gormsen
    British Journal of Haematology.2022; 197(2): 139.     CrossRef
  • Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT
    Hongyan Li, Min Wang, Yajing Zhang, Fan Hu, Kun Wang, Chenyang Wang, Zairong Gao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?
    Ross Thomas Salvaris, Chan Yoon Cheah
    Leukemia & Lymphoma.2022; 63(14): 3271.     CrossRef
  • Prognostic Values of Baseline 18F‐FDG PET/CT in Patients with Peripheral T‐Cell Lymphoma
    Yeye Zhou, Xiaoyi Zhang, Haifeng Qin, Zixuan Zhao, Jihui Li, Bin Zhang, Shibiao Sang, Yiwei Wu, Shengming Deng, Francesco Di Raimondo
    BioMed Research International.2020;[Epub]     CrossRef
  • The Incremental Prognostic Value of Baseline 18F‐FDG PET/CT Imaging in Angioimmunoblastic T‐Cell Lymphoma
    Hui Wang, Wenjing Yu, Tao Wu, Yangyang Xue, Dan Zhang, Huiqin Xu, Rosario Caltabiano
    BioMed Research International.2020;[Epub]     CrossRef
  • 10,427 View
  • 211 Download
  • 26 Web of Science
  • 23 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP